|
Cell line
|
Treatment
|
% subG1
|
% G1
|
% G2/M
|
% S
|
|---|
|
ML1 (FTC)
|
Untreated
|
0.39 ± 0.1
|
37.5 ± 2.1
|
30.5 ± 2.4
|
32.0 ± 2.2
|
|
24 h ABT-737
|
21.2 ± 2.9*
|
34.0 ± 3.1
|
21.5 ± 1.9*
|
44.5 ± 3.6*
|
|
FTC236 (FTC)
|
Untreated
|
0.21 ± 0.1
|
48.5 ± 4.4
|
24.1 ± 1.6
|
27.4 ± 2.0
|
|
24 h ABT-737
|
18.8 ± 2.0*
|
41.6 ± 3.9
|
20.3 ± 2.6
|
38.1 ± 2.9*
|
|
BHT101 (PTC)
|
Untreated
|
3.16 ± 2.8
|
65.1 ± 5.3
|
16.0 ± 1.7
|
18.9 ± 2.3
|
|
24 h ABT-737
|
54.8 ± 4.6*
|
42.6 ± 5.3*
|
16.1 ± 2.7
|
41.3 ± 5.0*
|
|
SW1736 (ATC)
|
Untreated
|
1.52 ± 0.4
|
54.9 ± 5.4
|
15.2 ± 2.2
|
29.9 ± 2.6
|
|
24 h ABT-737
|
39.9 ± 5.9*
|
42.8 ± 4.5*
|
13.2 ± 1.2
|
44.0 ± 3.6*
|
|
HTh7 (ATC)
|
Untreated
|
3.10 ± 0.2
|
60.1 ± 4.9
|
10.6 ± 0.8
|
29.3 ± 2.6
|
|
24 h ABT-737
|
11.1 ± 1.4*
|
59.6 ± 4.7
|
3.3 ± 0.4*
|
37.1 ± 2.6*
|
- Values for G1-, G2/M- and S-phase are determined for the living cells that were not included in the sub-G1-peak
- * Indicates significant change (p < 0.05, Student’s t test) compared to controls treated with vehicle
